Market Overview

XenoPort May Be Beneficiary of Biogen Patent Filings

Share:
Related BIIB
The Next Sector Rotation Will Be To Biotechs
Biogen Plans To Spin-Off Its Hemophilia Unit As Publicly Traded Firm
A Prescription For High Risk Fever (Seeking Alpha)
Related XNPT
XenoPort Continues Higher Amid Takeover Rumors
9 Stocks Moving In Friday's Pre-Market Session

Brian Abrahams, a Wells Fargo analyst, believes that Biogen (NASDAQ: BIIB) MS pill patents will be a positive boost for XenoPort (NASDAQ: XNPT).

Further patent applications could provide patent protection until 2032 for Biogen's BG-12, which should benefit XenoPort's '829 drug, an earlier stage derivative of BG-12, with added protection from generic competition.

BIIB is currently up 1.5 percent in pre-market trading, while XNPT is currently unchanged.

Latest Ratings for BIIB

DateFirmActionFromTo
Apr 2016Goldman SachsMaintainsNeutral
Apr 2016BMO CapitalInitiates Coverage onMarket Perform
Mar 2016BairdMaintainsNeutral

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings

 

Related Articles (BIIB + XNPT)

View Comments and Join the Discussion!